|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 38/17 | (2006.01) |
| A61K 38/08 | (2019.01) | ||
| A61K 38/10 | (2006.01) | ||
| A61K 38/44 | (2006.01) | ||
| A61K 39/00 | (2006.01) | ||
| A61K 38/19 | (2006.01) | ||
| A61K 38/20 | (2006.01) | ||
| A61K 45/06 | (2006.01) | ||
| C12N 9/02 | (2006.01) |
| (11) | Number of the document | 3320912 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17194619.7 |
| Date of filing the European patent application | 2009-04-17 | |
| (97) | Date of publication of the European application | 2018-05-16 |
| (45) | Date of publication and mention of the grant of the patent | 2021-03-31 |
| (46) | Date of publication of the claims translation | 2021-07-12 |
| (30) | Number | Date | Country code |
| 200800565 | 2008-04-17 | DK |
| (72) |
ANDERSEN, Mads Hald, DK
STRATEN, Per Thor, DK
|
| (73) |
IO BIOTECH ApS,
c/o COBIS Ole Maaloes Vej 3, 2200 Copenhagen N,
DK
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Indolamino 2,3-dioksigenaze grindžiama imunoterapija |
| INDOLEAMINE 2, 3-DIOXYGENASE BASED IMMUNOTHERAPY |
| Payment date | Validity (years) | Amount | |
| 2026-03-18 | 18 | 347.00 EUR |
| 2027-04-17 |